FRANKLIN LAKES, N.J. -- Collagen Matrix, Inc. has received the Food and Drug Administration (FDA)'s clearance of its 510(k) for Matrix Collagen Particles -- Wound Dressing. Matrix Collagen Particles is a safe, absorbent, microfibrillar particulate collagen matrix intended for the management of moderately to heavily exudating wounds and to control minor bleeding. These types of wounds include pressure ulcers, venous stasis ulcers, diabetic ulcers, acute wounds (trauma or surgical wounds), and partial-thickness burns.
Each year in the U.S., about 2.2 million patients are treated for diabetic ulcers, 3.1 million patients are treated for pressure ulcers, 650,000 patients are treated for venous stasis ulcers and 600,000 patients are treated for burns. In addition, there are about 135 million general and reconstructive procedures performed each year that may require the use of a wound dressing. Approximately $1 billion per year are spent on wound dressings.
The Matrix Collagen Particles product is the first of a line of wound-care products that the company is planning to develop. Its goal is to provide cost-effective solutions to the problem of treating topical wounds, particularly chronic wounds that are difficult to manage with currently available products on the market due to prohibitive cost structures or product ineffectiveness.
"The clinical applications of our proprietary collagen technology are immense in the health care industry. We hope to make an impact in the wound care market with an effective product that is also cost-effective," says Shu-Tung Li, PhD, Collagen Matrix's president and CEO.
Collagen Matrix, Inc. is a leader in the design and engineer of collagen-based extracellular matrices for tissue and organ repair and regeneration. Since its inception in 1997, the Company has received many government grants for the development of collagen-based matrix products in the areas of neurological and vascular tissue regeneration applications. The company currently manufactures collagen-based finished medical devices in the areas of oral surgery, neurosurgery and wound care. Collagen Matrix works cooperatively with its clients in tissue engineering R&D, product development, and customized matrix development.
Source: Collagen Matrix, Inc.
Beyond the Surface: Tackling the Sterilization Challenges of Flexible Endoscopes
May 26th 2025Flexible endoscopes revolutionized modern medicine—but their complex design poses persistent sterilization challenges. With mounting infection risks and emerging innovations, experts are rethinking how to clean and safeguard one of health care’s most indispensable tools.
Silent Saboteurs: Managing Endotoxins for Sepsis-Free Sterilization
Invisible yet deadly, endotoxins evade traditional sterilization methods, posing significant risks during routine surgeries. Understanding and addressing their threat is critical for patient safety.
Endoscopes and Lumened Instruments: New Studies Highlight Persistent Contamination Risks
May 7th 2025Two new studies reveal troubling contamination in both new endoscopes and cleaned lumened surgical instruments, challenging the reliability of current reprocessing practices and manufacturer guidelines.